A preliminary study in ovarian cancer cell lines showed HDAC inhibitors increased the sensitivity to cisplatin, therefore suggesting a combination of HDAC inhibitors and chemotherapy may be effective in targeting aggressive tumours [101]. Here, HDAC9 is linked to ovarian carcinoma.